At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 581 enrolled
Drug / intervention
Drug: Budesonide/formoterol (Symbicort Turbuhaler +2 moredrug
Likely dose
Drug: Budesonide/formoterol (Symbicort Turbuhaler 4.5µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Tolerability Study of Symbicort Turbuhaler(160/4.5µg/Inhalation,2inhalations Twice Daily) Added to Atrovent (20µg/Inhalation, 2 Inhalations 4 Times Daily)+Theophylline SR(0.1g/Tablet,1 Tablet p.o. Twice Daily) Compared With Atrovent+Theophylline SR in Severe COPD Patients.
In Brief
A Phase 4 clinical trial evaluating Drug: Budesonide/formoterol (Symbicort Turbuhaler, Drug: ipratropium (AtroventTM), and 1 other intervention for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 581 participants across 21 sites.
Detailed Summary
Efficacy and tolerability study in severe chronic obstructive pulmonary disease (COPD) patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 2011
Enrollment StartSep 2011
Primary CompletionDec 2012
TodayJul 2026
First PostedAug 12, 2011
Enrollment StartSep 1, 2011
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 14.9 years ago
Interventions
Drug: Budesonide/formoterol (Symbicort Turbuhalerdrug
budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily)
Drug: ipratropium (AtroventTM)drug
ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily)
theophylline SRdrug
theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)